remestemcel-L has NOT been rejected by the F
DA. A CRL is in fact "approved if you meet condition X". Unlike Regenaron it has a flawless safety profile. Regenaron is on a phase 1/2/3 trial and needs to meet the endpoints for each phase. It looks good so far, but is for a different stage of the disease and largely unrelated to us. It is not a revolutionary new way to treat inflammatory disease and therfore is indeed not in same league as MSB's products.
remestemcel-L has NOT been rejected by the FDA. A CRL is in fact...
-
- There are more pages in this discussion • 134 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.055(4.66%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.18 | $1.13 | $4.824M | 4.236M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 25589 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |